Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Cholangiocarcinoma 5Urinary Bladder Neoplasms 3Acrocephalosyndactylia 3Stomach Neoplasms 2Glioblastoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Upper Tract Urothelial Carcinomas 1Tumor With Alterations of the FGF-R 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oncogenic osteomalacia 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Hypophosphatemia 1Hematologic Neoplasms 1Glioma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × infigratinib × Clear all
NCT04424966 2025-10-24

Infigratinib in Recurrent High-Grade Glioma Patients

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Terminated
7 enrolled 18 charts
CNS

Glioblastoma, Glioma

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Novartis

Phase 2 Completed
26 enrolled 10 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡